BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25833198)

  • 1. Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.
    Kong JN; He Q; Wang G; Dasgupta S; Dinkins MB; Zhu G; Kim A; Spassieva S; Bieberich E
    Int J Cancer; 2015 Oct; 137(7):1610-20. PubMed ID: 25833198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression.
    Jung KA; Choi BH; Kwak MK
    Mol Pharmacol; 2015; 87(3):465-76. PubMed ID: 25534417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
    Imai Y; Ishikawa E; Asada S; Sugimoto Y
    Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
    Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
    Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
    Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
    Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
    Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
    Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
    Qin T; Huang G; Chi L; Sui S; Song C; Li N; Sun S; Li N; Zhang M; Zhao Z; Li L; Li M
    Biomed Pharmacother; 2017 Nov; 95():649-655. PubMed ID: 28881292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
    Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
    Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
    Shepard RL; Cao J; Starling JJ; Dantzig AH
    Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
    Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
    Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
    Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
    Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters.
    Rigalli JP; Tocchetti GN; Arana MR; Villanueva SS; Catania VA; Theile D; Ruiz ML; Weiss J
    Cancer Lett; 2016 Jun; 376(1):165-72. PubMed ID: 27033456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
    Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
    Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin.
    Hekmatirad S; Moloudizargari M; Moghadamnia AA; Kazemi S; Mohammadnia-Afrouzi M; Baeeri M; Moradkhani F; Asghari MH
    Front Immunol; 2021; 12():692654. PubMed ID: 34149737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.